Pregabalin is chemically related to the antiepileptic drug gabapentin and is a successor to it for management of neuropathic pain as well as an adjunct therapy for the management of partial onset seizures. Gabapentin, a GABA receptor agonist, is an approved as add-on therapy for intractable partial seizures in adults. Clinical trials of pregabalin started in 2000. It was approved by the FDA in 2004. In 2005 the Drug Enforcement Administration placed pregabalin into Schedule V of the Controlled Substances Act. As a result of this rule, the regulatory controls and criminal sanctions of Schedule V will be applicable to the manufacture, distribution, dispensing, importation and exportation of pregabalin and products containing pregabalin.